More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$124.67B
EPS
38.8
P/E ratio
25.1
Price to sales
0.27
Dividend yield
0.348%
Beta
0.274771
Previous close
$1,082.59
Today's open
$1,075.23
Day's range
$1,067.38 - $1,081.47
52 week range
$723.68 - $1,121.50
show more
CEO
Brian S. Tyler
Employees
43000
Headquarters
Irving, TX
Exchange
New York Stock Exchange
Shares outstanding
115456664
Issue type
Common Stock
Healthcare
Medical Distributors
Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs
McKesson Corporation (MCK) shares up over 235% since May 2022 thanks to institutional support.
FXEmpire • Nov 11, 2026

Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Zacks Investment Research • Nov 11, 2026

3 Reasons Why Growth Investors Shouldn't Overlook McKesson (MCK)
McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
Zacks Investment Research • Nov 10, 2026

McKesson Q2 Earnings Call Highlights
McKesson NYSE: MCK raised its fiscal 2027 adjusted earnings outlook after reporting higher second-quarter revenue and profit, supported by prescription volumes, specialty distribution and demand for medication access services.
MarketBeat • Nov 7, 2026

McKesson Corporation (MCK) Hit a 52 Week High, Can the Run Continue?
McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Research • Nov 6, 2026

McKesson (MCK) Upgraded to Buy: Here's What You Should Know
McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • Nov 6, 2026

MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
McKesson's Q2 fiscal 2027 earnings beat estimates on specialty growth and higher prescription volumes, prompting raised guidance despite an after-hours stock dip.
Zacks Investment Research • Nov 5, 2026

MCK Q2 Earnings Call Highlights Raised Outlook and Specialty Growth
McKesson raises its fiscal 2027 earnings outlook after strong Q2 results, fueled by specialty drug demand, operating gains and higher-margin healthcare expansion.
Zacks Investment Research • Nov 5, 2026

Bristol Gate U.S. Equity Q3 2026 Portfolio Review
Microsoft was the largest contributor, with its shares up 37.8% for the quarter. KLA and Applied Materials were the largest detractors, falling 35.3% and 29.2%. On a relative basis, three of the largest detractors were companies we did not own: NVIDIA, Apple, and Meta, which rose 14.3%, 15.2%, and 28.8%. We made one change to the portfolio during the quarter, purchasing Garmin and selling Verisk, and rebalanced outliers back to approximately equal weights during the same trade window.
Seeking Alpha • Nov 5, 2026

The Biggest Drug Wholesaler Just Crushed Earnings Views — Here's What To Know
McKesson stock was flat late Wednesday, though the drug wholesaler topped fiscal second-quarter views and hiked its earnings guide.
Investors Business Daily • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell McKesson Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.